Demographic, clinical and laboratory characteristics of the study population by method of follow-upa.

aAll data are n (%) or mean (SD).*Includes d4T-3TC-EFV, ZDV-3TC-NVP, NVP-TDF-3TC, ZDV-ddI-LPV/r, ZDV-3TC-LPV/r, ddI-d4T-LPV/r, ZDV-EFV-LPV/r, 3rd line drugs and unknown drugs.**Includes D4T-3TC-NVP, D4T-3TC-EFV, TDF-FTC-EFV, NVP-TDF-3TC, TDF-FTC-NVP, ZDV-DDI-LPV/r, ZDV-3TC-LPV/r, DDI-D4T-LPV/r, TDF-FTC-LPV/r, ZDV-TDF-LPV/r, ZDV-3TC-DDI-LPV/r , TDF-EFV-LPV/r, 3TC-NVP-LPV/r and other 3rd line drugs.ΨN = 807.SOC: standard of care; PRP: Pharmacy Refill Program; ART: antiretroviral treatment; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; ZDV: zidovudine; EFV: efavirenz; TDF: tenofovir; FTC: emtricitabine; LPV/r: lopinavir/ritonavir; OI: opportunistic infection.